Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep1190 | Late Breaking | ECE2022

NanoLuc® Binary Technology to explore the mechanism of action of a Magmas inhibitor

Borges de Souza Patricia , Gagliardi Irene , Ambrosio Maria Rosaria , Bondanelli Marta , Zatelli Maria Chiara

Introduction: Magmas encodes for an integral constituent of the TIM23 translocase complex located in the mitochondrial inner membrane that drives proteins from the intermembrane space into the mitochondrial matrix by functionally interacting with Tim14. We previously demonstrated that Magmas silencing is able to sensitize ACTH-secreting mouse pituitary adenoma cells to pro-apoptotic stimuli, reduce DNA synthesis, accumulate cells in G0/G1 phase with concomitant decrease in S p...

ea0020p592 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Glucose metabolism alterations in acromegaly

Ambrosio Maria Rosaria , Malaspina Alessandra , De Paola Grazia , Bondanelli Marta , Zatelli Maria Chiara , degli Uberti Ettore

Glucose metabolism alterations are frequently observed in acromegalic patients. Somatostatin analogues (SSTA) are the most widely used drugs to treat acromegaly, since they inhibit GH and IGF-1 levels, reduce pituitary mass, but can affect glucose metabolism. Aim of our study was to evaluate glucose metabolism alterations in acromegalic patients cured after surgery and in patients with active disease during treatment with SSTA. We studied 10 patients (group A, 5F, 55.66±1...

ea0016p316 | Endocrine tumours | ECE2008

Effects of pasireotide on bronchial carcinoids in primary culture

Zatelli Maria Chiara , Tagliati Federico , Luchin Andrea , Bondanelli Marta , Rea Federico , degli Uberti Ettore

Bronchopulmonary endocrine tumors represent 25–30% of lung neoplasms. Surgery provides good survival for differentiated tumors (typical and atypical carcinoids), but is not useful for aggressive poorly differentiated forms. Somatostatin (SRIF) analogs can be used as medical therapy, prolonging patient survival. However, the compounds employed so far did not display antiproliferative effects. Recently, a new stable SRIF analog, pasireotide (SOM230), which activates SSTR1, ...

ea0020p29 | Adrenal | ECE2009

Glucocorticoid replacement therapy in adrenocortical insufficiency

Carli Anna Rita , Frigato Gemma , Bondanelli Marta , Zatelli Maria Chiara , Ambrosio Maria Rosaria , de gli Uberti Ettore

The effectiveness of glucocorticoid replacement therapy is based on clinical criteria, since objectives parameters are not standardized. The purpose of our study was to assess the adequacy of replacement therapy with cortisone acetate, trying to identify parameters indicating proper replacement. We studied 22 patients with adrenal insufficiency (7 primary and 15 secondary) treated with cortisone acetate (mean daily dose 36.5+/−2.1 mg at 0800 a.m. and 0300 p.m.), and six ...

ea0081p431 | Pituitary and Neuroendocrinology | ECE2022

Acromegaly and aging: a double hit against quality of life?

Gagliardi Irene , Chiloiro Sabrina , Vallillo Maria , Bondanelli Marta , Volpato Stefano , Giampietro Antonella , Bianchi Antonio , De Marinis Laura , Chiara Zatelli Maria , Rosaria Ambrosio Maria

Introduction: Acromegaly patients (ACRO) show increased morbidity that affects health and quality of life (QoL). Elderly ACRO are going to increase in the next few years, but evidence regarding their management is lacking.Aim: To evaluate physical, functional and cognitive performances of elderly ACRO and the relationship with QoL.Methods: Multicenter case-control study conducted on 42 older ACRO (≥ 65 years) compared to an a...

ea0063gp87 | Thyroid Nodules and Cancer | ECE2019

Intronic RAS and PI3KCA mutations identified by Next Generation Sequencing in thyroid nodules with indeterminate cytology may associate with follicular thyroid cancer

Borges de Souza Patricia , Rossi Lucrezia , Crociara Anna , Rossi Roberta , Ambrosio Maria Rosaria , Rossi Martina , Bondanelli Marta , Lanza Giovanni , Zatelli Maria Chiara

Introduction: Accurately discern malignant from benign nodules sometimes represents a real challenge. Fine needle aspiration (FNA) biopsy, ultrasound and The Bethesda System for Reporting Thyroid Cytopathology (BSRTC) allow for accurate diagnosis in 60–80% of all nodules. However, 10–20% of thyroid FNAs yield an indeterminate cytology (BSRTC III and IV categories). The real malignancy rate of BSRTC III category is difficult to ascertain because histopathological anal...

ea0037gp.28.04 | Endocrine tumours and neoplasia – NETS | ECE2015

Receptor tyrosine kinase expression and their role in the response to target therapy in bronchopulmonary NET

Gagliano Tersa , Benfini Katiusci , Gentilin Erica , Falletta Simona , Bondanelli Marta , Di Pasquale Carmelina , Riva Eleonora , degli Ubertu Ettore , Zatelli Maria Chiara

Surgery is not feasible for infiltrating and metastatic bronchopulmonary NET (BP-NET). In those cases, medical therapy is tried with controversial results. Thus, it is important to identify new therapeutic targets to provide adequate medical treatment for patients with BP-NET. Sunitinib, is a multi-targeted receptor tyrosine kinase inhibitor (TKI), mainly described to inhibit VEGFR.The aim of our study is to verify whether insulin receptor (IR), IGF1R, a...

ea0037gp.29.05 | Endocrine tumours and neoplasia – Adrenal Tumour | ECE2015

EGFR as potential new molecular target in the medical treatment of adrenocortical cancer

Gagliano Teresa , Balboni Francesco , Pasquale Carmelina Di , Gentilin Erica , Benfini Katiusci , Falletta Simona , Bondanelli Marta , Franceschetti Paola , Feo Carlo , Uberti Ettore degli , Zatelli Maria Chiara

Adrenocortical cancer (ACC) is a rare and aggressive malignancy. Currently the main therapeutic option is surgery, but due to difficult and delayed diagnosis and to the onset of metastases, medical therapy is often tried. ACC treatment is mainly represented by Mitotane alone or in association with chemotherapy, with variable results. Understanding the molecular mechanisms that regulate ACC proliferation could be useful to identify new therapeutic options. Sunitinib, a multitar...

ea0037ep169 | Reproduction, endocrine disruptors and signalling | ECE2015

Differential cell cycle control protein profiles characterise bronchial carcinoids sensitive to mTOR inhibitors

Benfini Katiuscia , Gagliano Teresa , Gentilin Erica , Riva Eleonora , Falletta Simona , Di Pasquale Carmelina , Bondanelli Marta , Ambrosio Maria Rosaria , degli Uberti Ettore Ciro , Zatelli Maria Chiara

Background: Bronchial carcinoids (BC) are rare neoplasm, still orphan of medical therapy, which arise from neuroendocrine cells. It has been previously demonstrated that the atypical BC human cell line NCI-H720 is sensitive to everolimus (E), an m-TOR inhibitor, in terms of cell viability reduction, with a G0 cell-cycle arrest and a Cyclin D1 protein reduction. On the contrary, the typical human BC cell line NCI-H727 is not sensitive to E, despite the Cyclin D1 reduction. The ...

ea0020p210 | Endocrine tumours and neoplasia | ECE2009

Recurrence in patients with pituitary nonfunctioning adenoma

De Paola Grazia , Buzoianu Roxana Elena , Bondanelli Marta , Trasforini Giorgio , Zatelli Maria Chiara , Laparelli Marcello , Cavazzini Luigi , Ambrosio Maria Rosaria , degli Uberti Ettore

Nonfunctioning adenomas (NFA) are 30% of all pituitary adenomas. Transphenoidal surgery is the first line therapy, but recurrences are frequent (12% al 69%). NFA treatment and follow-up are controversial. Aim of our study was to evaluate the recurrence prevalence and the factors associated with tumor aggressiveness in patients with NFA. We studied 30 patients that underwent surgery: 14 patients (group A, 7F, 3.92±12.48 years) with and 16 patients (group B, 6F, 56.5±1...